Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients

• Kristine A. Frerichs,
• Patricia W.C. Bosman,
• Jeroen F. van Velzen,
• Pieter L.A. Fraaij,
• Marion P.G. Koopmans,
• Guus F. Rimmelzwaan,
• Inger S. Nijhof,
• Andries C. Bloem,
• Tuna Mutis,
• Sonja Zweegman,
• Niels W.C.J. van de Donk

Affiliations

Kristine A. Frerichs

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam

Patricia W.C. Bosman

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam

Jeroen F. van Velzen

University Medical Center, Laboratory of Translational Immunology, Utrecht

Pieter L.A. Fraaij

Erasmus Medical Center, Department of Viroscience, National Influenza Center, Rotterdam, the Netherlands

Marion P.G. Koopmans

Erasmus Medical Center, Department of Viroscience, National Influenza Center, Rotterdam, the Netherlands

Guus F. Rimmelzwaan

Erasmus Medical Center, Department of Viroscience, National Influenza Center, Rotterdam, the Netherlands

Inger S. Nijhof

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam

Andries C. Bloem

University Medical Center, Laboratory of Translational Immunology, Utrecht

Tuna Mutis

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam

Sonja Zweegman

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam

Niels W.C.J. van de Donk

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam